Insights

Growing Market Presence NIOX Group has established strategic partnerships with Vitalograph Inc and the AHSN Network, enhancing its distribution channels and visibility in the medical device market, which creates opportunities for expanding sales efforts in healthcare networks.

Innovative Product Focus With its flagship NIOX VERO® device leading the global FeNO testing market, there is significant potential to promote related diagnostic tools and accessories to healthcare providers looking to adopt non-invasive, accurate asthma management solutions.

Expanding Asthma & COPD Solutions Beyond asthma, the company's launch of COPD treatment devices like Duaklir Pressair indicates an opportunity to cross-sell comprehensive respiratory care products to clinics and hospitals managing multiple respiratory conditions.

Market Reach & Growth Operating with an annual revenue of up to 10 million dollars and a strong reputation for innovation, NIOX presents a viable sales target for healthtech suppliers aiming to enter the asthma diagnostics and respiratory device market segment.

Technological Adoption The company's use of advanced tech stacks including cloud services and digital marketing channels such as LinkedIn Ads signals openness to leveraging cutting-edge sales tools, data-driven marketing, and telehealth integrations to reach healthcare professionals more effectively.

Similar companies to FeNO by NIOX® USA

FeNO by NIOX® USA Tech Stack

FeNO by NIOX® USA uses 8 technology products and services including LinkedIn Ads, BootstrapCDN, Preact, and more. Explore FeNO by NIOX® USA's tech stack below.

  • LinkedIn Ads
    Advertising
  • BootstrapCDN
    Content Delivery Network
  • Preact
    Javascript Libraries
  • jQuery Migrate
    Javascript Libraries
  • FancyBox
    Javascript Libraries
  • UNIX
    Operating Systems
  • reCAPTCHA
    Security
  • Cloudflare Bot Management
    Security

FeNO by NIOX® USA's Email Address Formats

FeNO by NIOX® USA uses at least 2 format(s):
FeNO by NIOX® USA Email FormatsExamplePercentage
First.Last@circassia.comJohn.Doe@circassia.com
85%
FirstLast@circassia.comJohnDoe@circassia.com
4%
First.Middle@circassia.comJohn.Michael@circassia.com
1%
First-Last@circassia.comJohn-Doe@circassia.com
2%
FiLast@circassia.comJoDoe@circassia.com
1%
First_Last@circassia.comJohn_Doe@circassia.com
1%
Last.First@circassia.comDoe.John@circassia.com
1%
LastFir@circassia.comDoeJoh@circassia.com
1%
FirstLa@circassia.comJohnDo@circassia.com
1%
F-Last@circassia.comJ-Doe@circassia.com
1%
Last.F@circassia.comDoe.J@circassia.com
1%
First@circassia.comJohn@circassia.com
1%
First.Last@niox.comJohn.Doe@niox.com
71%
FirLast@niox.comJohDoe@niox.com
17%
FiLast@niox.comJoDoe@niox.com
6%
FLast@niox.comJDoe@niox.com
6%

Frequently Asked Questions

Where is FeNO by NIOX® USA's headquarters located?

Minus sign iconPlus sign icon
FeNO by NIOX® USA's main headquarters is located at 1100 Perimeter Park Drive Suite 114 Morrisville, North Carolina 27560 United States. The company has employees across 3 continents, including North AmericaEuropeAsia.

What is FeNO by NIOX® USA's official website and social media links?

Minus sign iconPlus sign icon
FeNO by NIOX® USA's official website is niox.com and has social profiles on LinkedIn.

What is FeNO by NIOX® USA's NAICS code?

Minus sign iconPlus sign icon
FeNO by NIOX® USA's NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does FeNO by NIOX® USA have currently?

Minus sign iconPlus sign icon
As of February 2026, FeNO by NIOX® USA has approximately 8 employees across 3 continents, including North AmericaEuropeAsia. Key team members include Chief Executive Officer: S. H.Chief Operating Officer: J. E.Chief Commercial Officer: L. S.. Explore FeNO by NIOX® USA's employee directory with LeadIQ.

What industry does FeNO by NIOX® USA belong to?

Minus sign iconPlus sign icon
FeNO by NIOX® USA operates in the Medical Equipment Manufacturing industry.

What technology does FeNO by NIOX® USA use?

Minus sign iconPlus sign icon
FeNO by NIOX® USA's tech stack includes LinkedIn AdsBootstrapCDNPreactjQuery MigrateFancyBoxUNIXreCAPTCHACloudflare Bot Management.

What is FeNO by NIOX® USA's email format?

Minus sign iconPlus sign icon
FeNO by NIOX® USA's email format typically follows the pattern of First.Last@circassia.com. Find more FeNO by NIOX® USA email formats with LeadIQ.

When was FeNO by NIOX® USA founded?

Minus sign iconPlus sign icon
FeNO by NIOX® USA was founded in 2006.

FeNO by NIOX® USA

Medical Equipment ManufacturingNorth Carolina, United States2-10 Employees

NIOX Group plc is a company that specialises in the development, manufacture, and distribution of medical devices for the diagnosis and monitoring of asthma. Their flagship product, NIOX VERO®, is a non-invasive medical device that measures fractional exhaled nitric oxide (FeNO) levels in patients with asthma.

NIOX VERO® provides accurate and reliable results, allowing healthcare
professionals to make informed decisions about the diagnosis and management of asthma. It is easy to use, and can be used in a variety of settings, including clinics, hospitals, and primary care settings.

The NIOX Group plc is committed to improving the lives of people with asthma and is dedicated to innovation and excellence in its products and services. NIOX® is also committed to offering additional training and support for healthcare professionals.

Overall, NIOX Group plc is the global leader in FeNO testing, with a strong
reputation for innovation and excellence in the development of medical devices for the diagnosis and management of asthma. With NIOX VERO®, healthcare professionals have a reliable and non-invasive tool to help them better diagnose and manage asthma.

References:
1. Alving K et al. Validation of a new portable exhaled nitric oxide analyzer, NIOX VERO®: randomized studies in asthma. Pulm Ther. 2017;3:207-218.
2. Gao J et al. Association between fractional exhaled nitric oxide, sputum induction and peripheral blood eosinophil in uncontrolled asthma. Allergy, Asthma & Clinical Immunology. 2018;1
3. Busse WW et al. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Lancet Respir Med. 2021;9(10):1165-1173.
4. Menzies-Gow A et al. Clinical utility of fractional exhaled nitric oxide in severe asthma management. Eur Respir J. 2020;55(3):1901633.
5. NIOX®. Data on File; MKT-DOF-007.

Section iconCompany Overview

Headquarters
1100 Perimeter Park Drive Suite 114 Morrisville, North Carolina 27560 United States
Website
niox.com
NAICS Code
3391 - Medical Equipment and Supplies Manufacturing
Founded
2006
Employees
2-10

Section iconFunding & Financials

  • $1M$10M

    FeNO by NIOX® USA's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $1M$10M

    FeNO by NIOX® USA's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.